GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Context Therapeutics Inc (NAS:CNTX) » Definitions » PB Ratio

Context Therapeutics (Context Therapeutics) PB Ratio : 2.30 (As of May. 14, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Context Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-14), Context Therapeutics's share price is $1.71. Context Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 was $0.74. Hence, Context Therapeutics's PB Ratio of today is 2.30.

The historical rank and industry rank for Context Therapeutics's PB Ratio or its related term are showing as below:

CNTX' s PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 2.7
Current: 2.31

During the past 5 years, Context Therapeutics's highest PB Ratio was 2.70. The lowest was 0.00. And the median was 0.00.

CNTX's PB Ratio is ranked better than
53.58% of 1312 companies
in the Biotechnology industry
Industry Median: 2.48 vs CNTX: 2.31

During the past 12 months, Context Therapeutics's average Book Value Per Share Growth Rate was -65.80% per year.

Back to Basics: PB Ratio


Context Therapeutics PB Ratio Historical Data

The historical data trend for Context Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Context Therapeutics PB Ratio Chart

Context Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
- - 0.88 0.30 1.52

Context Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.30 0.31 1.06 1.31 1.52

Competitive Comparison of Context Therapeutics's PB Ratio

For the Biotechnology subindustry, Context Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Context Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Context Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Context Therapeutics's PB Ratio falls into.



Context Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Context Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=1.71/0.744
=2.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Context Therapeutics  (NAS:CNTX) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Context Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Context Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Context Therapeutics (Context Therapeutics) Business Description

Traded in Other Exchanges
Address
2001 Market Street, Suite 3915, Unit No. 15, Philadelphia, PA, USA, 19103
Context Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer.
Executives
Martin A. Lehr director, officer: Chief Executive Officer 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Jennifer Lynn Minai-azary officer: Chief Financial Officer 110 MILLER AVENUE, SUITE 100, ANN ARBOR MI 48104
Alex C. Levit officer: Chief Legal Officer, Corp. Sec 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Tarek Sahmoud officer: Chief Medical Officer 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Richard J Berman director 305 COLLEGE ROAD EAST, PRINCETON NJ 08540
Jennifer Evans Stacey director AUXILIUM PHARMACEUTICALS, INC., 160 WEST GERMANTOWN PIKE, NORRISTOWN PA 19401
Linda West director C/O GALERA THERAPEUTICS, INC., 2 W LIBERTY BLVD., #110, MALVERN PA 19355
Evan G. Dick officer: SVP of R&D 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
William F. Rencher officer: Head of CMC and Regulatory 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Philip W. Kantoff director 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104

Context Therapeutics (Context Therapeutics) Headlines